New methods for evaluating lymphoma treatment response using PET/CT imaging
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
Ruijin Hospital · NCT06795113
This study is testing a new way to see how well lymphoma treatments are working by looking at PET/CT scans from 4,000 patients to help doctors make better decisions about care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06795113 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a novel approach for assessing treatment response in patients with high-metabolic lymphoma by analyzing PET/CT imaging data. It involves a multicenter retrospective cohort design, utilizing data from 2,000 patients treated at Ruijin Hospital and an additional 2,000 patients from other institutions. The study compares end-of-treatment PET results with interim PET results to establish a new response assessment method, contrasting it with the existing Lugano classification criteria. The goal is to provide clinicians with more accurate tools for evaluating treatment efficacy and predicting patient prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histopathologically confirmed high-metabolic lymphoma who have undergone 18F-FDG PET/CT imaging at various treatment stages.
Not a fit: Patients with a history of prior antitumor treatment or other concurrent malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate evaluations of treatment response in lymphoma, improving patient management and outcomes.
How similar studies have performed: Other studies have shown success in using PET/CT imaging for lymphoma assessment, but this specific approach is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histopathologically confirmed high-metabolic lymphoma 2. Underwent 18F-FDG PET/CT imaging before, during, and after treatment 3. Treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations 4. Complete clinicopathological and follow-up data available Exclusion Criteria 1: History of prior antitumor treatment 2: History of other malignancies 3: Incomplete clinical data or imaging records 4: Presence of other concurrent malignant tumors
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Rui Guo
- Email: gr11734@rjh.com.cn
- Phone: 13361860108
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoma, PET/CT, lymphoma, 18F-FDG